KATIE MCCRARY: Open Payments
NPI 1205457728 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$980 in 50 payments from 9 companies in 2025. Trend: 2023 $470 · 2024 $937 · 2025 $980
Food & beverage: $980
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 18 | $401 |
| Otsuka America Pharmaceutical, Inc. | 12 | $177 |
| AstraZeneca Pharmaceuticals LP | 8 | $150 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $107 |
| Incyte Corporation | 2 | $47 |
| Lilly USA, LLC | 2 | $45 |
| TMS NeuroHealth Centers Inc. | 1 | $19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: Rybelsus, REXULTI, Kerendia, Ozempic, FARXIGA, JARDIANCE, AIRSUPRA, OPZELURA.
Industry payments across TX — which companies pay providers there.
